Screener / SEC EDGAR /CIK 0001082554 /10-K filed Feb 25, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

UNITED THERAPEUTICS Corp UTHR

Compare with peers Embed
Cash returned and share count

No buyback or stock pay figures in its 10-K data yet

XBRL, 10-K

Where the cash came from and where it went

FY2025, from the cash flow statement in the 10-K, added up

Operating cash flowShares soldCash on hand usedCapital spendingBuybacksOther, net Operating cash flow: $1.6B Operating cash flow $1.6B Shares sold: $173.9M Shares sold $173.9M Cash on hand used: $140.1M Cash on hand used $140.1M Capital spending: $520.5M Capital spending $520.5M Buybacks: $1.0B Buybacks $1.0B Other, net: $354.7M Other, net $354.7M

Each number is a line of the cash flow statement as the company tagged it. "Other, net" is what those lines do not cover (investments bought and sold, other financing and investing lines, and exchange rates); Tickdelta does not estimate it.

Where the operating cash went, year by year

FY2016 to FY2025 · cash flow statements, 10-K XBRL

10 years
Operating cash, added up $7.7B 10 fiscal years, FY2016 to FY2025
Reinvested - not shown: operating cash was negative in a year of the span
Returned to owners - not shown: operating cash was negative in a year of the span
Debt repaid - gross repayments added up; debt that was refinanced counts each time
Fiscal yearOperating cashCapital spendingAcquisitionsBuybacks
Dec 31, 2025 $1.6B $520.5M-$1.0B
Dec 31, 2024 $1.3B $246.5M-$1.0B
Dec 31, 2023 $978.0M $230.4M$89.2M-
Dec 31, 2022 $802.5M $138.8M--
Dec 31, 2021 $598.2M $120.8M--
Dec 31, 2020 $755.7M $59.3M--
Dec 31, 2019 -$206.6M $83.7M--
Dec 31, 2018 $778.4M $184.4M$124.1M-
Dec 31, 2017 $474.2M $86.3M-$250.0M
Dec 31, 2016 $643.6M $38.0M$5.2M$500.0M
Added up$7.7B $1.7B$218.5M$2.8B

Each bar is one fiscal year; its colours add up to what the cash flow statement says the company spent on each line, and the line across it is that year's operating cash flow. Spending above the line was paid from new debt, shares sold or cash on hand. A bar part links to the 10-K it comes from. A line the company did not report is left out, not estimated, so the shares are of operating cash only and can add up to more or less than 100%. Debt repaid is the gross amount, so refinanced debt is counted each time it is repaid. A reading aid, not a grade: Tickdelta does not say whether a split was good. Banks and insurers are left out.

Buybacks, dividends and share count

Year by year · XBRL, each 10-K

No buyback or share count data in the 10-K XBRL.

Buybacks month by month, and what is left to buy

Share buybacks · 10-Q, Part II Item 2, latest 4 quarters

“As announced on March 9, 2026, our Board approved a share repurchase program authorizing up to $2.0 billion in aggregate repurchases of our common stock, which program expires on March 9, 2027.”

10-Q, Part II Item 2

“Pursuant to this authorization, we entered into the March 2026 ASRs, comprised of a $750.0 million uncollared share repurchase agreement and a $750.0 million collared share repurchase agreement (the March 2026 Collared ASR), with Citi to repurchase approximately $1.5 billion of our common stock.”

10-Q, Part II Item 2
MonthShares boughtAverage price
Sep 2026 739,993 $492.61
Aug 2026 240,401 $536.06
Jun 2026 378,936 $547.02

Shares and average price are the numbers in the 10-Q table, row by row; "shares × price" is our multiplication of the two. A row with a price of "-" is an accelerated repurchase paid up front, where the 10-Q does not give a price yet. A 10-Q that counts shares in millions gives a rounded number, shown as "about". Shares withheld for employees' taxes are not in this table. A month that no 10-Q table gives, or that this page could not read with confidence, is not shown.

What the 10-Ks show for each CEO's years

Each CEO's years · the CEO of each fiscal year as named in the proxy's pay versus performance table

Martine Rothblatt

FY2025 · 1 year in the table
Operating cash flow
$1.6B
Capital spending
$520.5M
Buybacks
$1.0B
Stock-based pay
$147.7M
Diluted shares since FY2024
-1.2%
Revenue since FY2024
+11%
CEO pay (reported)
$18.0M
The proxy that names the CEO

Sources

The cash flow statement, dividends per share and diluted share count in each 10-K's XBRL; Part II Item 2 of each 10-Q for monthly buybacks; offering prospectuses (S-3, 424B) for new shares; Form D data sets for private raises.

Also

CEO pay: what the CEO was paid over the same years.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/UTHR/export.csv") into a cell.

Next:CEO pay
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.